Delcath Systems, Inc. is an interventional oncology company building a commercial business around HEPZATO KIT, a drug and device combination product approved by the FDA for metastatic hepatic dominant uveal melanoma. The stock trades near the upper end of a wide fifty two week range, a level that already prices in the first sustained profitable year the company has delivered.
The case for the stock rests on a sharp earnings inflection. Full year revenue nearly doubled year over year, the company swung from a substantial net loss to positive net income, and HEPZATO product revenue accelerated in the most recent half. Operating cash flow turned meaningfully positive, and the balance sheet carries no interest bearing debt.
The bear case is that the approved indication is a rare disease with a small patient base, and the addressable market for the single approved use is modest. The stock trades at a rich multiple of sales on that base, which means the valuation depends on the clinical expansion story rather than on the current revenue line.
Three named variables drive the thesis. First is the site and procedure ramp in the United States, where the number of centers treating at least one patient roughly doubled in the most recent fiscal year. Second is the readout from the two active Phase 2 combination trials in liver dominant metastatic colorectal cancer and metastatic breast cancer. Third is the pricing and reimbursement environment created by the new government rebate and 340B obligations.